Andere Sprachen Inhibikase Therapeutics, Inc.

Aktien

A3EMJR

US45719W2052

IKT

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:56:29 30.04.2024			% 5 Tage	% 1. Jan.
1.47 ^USD	-7.55%		-6.33%	+16.54%

03.04.	Inhibikase Therapeutics kündigt Pre-IND Meeting mit der FDA für IkT-001Pro bei pulmonaler arterieller Hypertonie an	CI
28.03.	Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	18.04.
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03.04.
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03.04.
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501	27.03.
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity	27.03.
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	07.03.
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	07.03.
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro	28.02.
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	07.02.
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	07.02.
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	07.02.
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	30.01.
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29.01.
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29.01.
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29.01.
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli	16.01.
Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024	16.01.
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	19.12.
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	19.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Inhibikase Therapeutics, Inc.

Aktien

A3EMJR

US45719W2052

IKT

Andere Sprachen

Filter